Summary
The bioavailability of a new controlled release formulation of indomethacin lysine salt in tablets was tested in 6 healthy humans against a conventional indomethacin lysinate formulation in capsules. Both contained 100 mg of the drug, i.e. 70 mg indomethacin. Peak plasma levels were lower and more lasting and the AUC was higher with the new controlled release formulation. The latter on average produced active plasma levels for 12 h, and so it can be recommended for twice daily administration.
References
Baber N, Halliday LDC, Van Den Heuvel WJA, Walker RW, Sibeon R, Keenan JP, Littler T, Orme M (1979) Indomethacin in rheumatoid arthritis: Clinical effects, pharmacokinetics and platelet studies in responders and nonresponders. Ann Rheum Dis 38: 128–137
Helleberg L (1981) Clinical pharmacokinetics of indomethacin. Clin Pharmacokinet 6: 245–258
Huskisson EC (1979) Routine drug treatment of rheumatoid arthritis and other rheumatic diseases. Clin Rheum Dis 5: 697–706
Flower RJ, Moncada S, Vane JR (1985) Analgesic — antipyretics and anti-inflammatory agents: drugs employed in the treatment of gout. In: Goodman Gilman A, Goodman LS, Rall TW, Murad F (eds) The pharmacological basis of therapeutics, 7 edn. McMillan New York, pp 695–697
Rhymer AR, Gengos DC (1979) Indomethacin. Clin Rheum Dis 5: 541–552
Boardman PL, Hart FD (1967) Side-effects of indomethacin. Ann Rheum Dis 26: 127–132
Rothermich NO (1966) An extended study of indomethacin. J Am Med Assoc 195: 531–536
Alvàn G, Orme M, Bertilsson L, Ekstrand R, Palmer L (1975) Pharmacokinetics of indomethacin. Clin Pharmacol Ther 18: 364–373
Meier J, Nuesch E, Schmidt R (1974) Pharmacokinetic criteria for the evaluation of retard formulations. Eur J Clin Pharmacol 7: 429–432
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Marzo, A., Reiner, A., Arrigoni Martelli, E. et al. Bioavailability of indomethacin from a modified release system containing indomethacin as the lysine salt. Eur J Clin Pharmacol 32, 85–87 (1987). https://doi.org/10.1007/BF00609963
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00609963